# Rucaparib with radiation after incomplete response to chemotherapy

Source: https://onco.cc/trials/nct03542175/  
OnCo record `nct03542175` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This completed study tested a DNA-repair drug with radiation after breast surgery. It does not offer new enrollment.

## Summary

Registry status completed, last updated 2025-12-08. Enrollment is 31 actual. Residual non-metastatic TNBC or selected high-risk hormone-receptor-positive/HER2-negative disease after neoadjuvant chemotherapy and definitive surgery. Dose escalation studied rucaparib concurrently with radiotherapy and additional maintenance. The registry design is phase 1; completion is not evidence of adjuvant efficacy.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-10-10
- Registry id: NCT03542175
- Phase: 1
- Setting: Residual non-metastatic TNBC or selected high-risk hormone-receptor-positive/HER2-negative disease after neoadjuvant chemotherapy and definitive surgery
- Sponsor: Memorial Sloan Kettering Cancer Center
- Enrolled: 31

## Sources

- ClinicalTrials.gov NCT03542175: https://clinicaltrials.gov/study/NCT03542175

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [Rucaparib](https://onco.cc/drugs/rucaparib/)

---
JSON: https://onco.cc/api/v1/entities/nct03542175.json